Table 3.

Multivariate analysis of factors associated with acromegaly control during the first 10 years in ACROSTUDY.

		Multivariate analysis				Pairwise comparison
Characteristics	Mean ± s.d. Peg dose at last visit/end of follow-up	Effect sizea	95% CI		P	P
Medications for acromegaly
Peg only	15.3 ± 9.1	0.35	0.32	0.39	<0.0001	Reference
Peg/other (non-SSA)	19.3 ± 12.3	0.47	0.39	0.55	0.4182	0.0074
Peg/SSA	14.3 ± 9.7	0.44	0.39	0.50	0.0378	0.0015
Peg/SSA/Other	22.1 ± 17.4	0.50	0.41	0.59	0.9683	0.0031
Interaction between time and medications for acromegaly		–	–	–	0.0061
IGF-1 value at baseline (µg/L)
<300	12.3 ± 8.8	0.29	0.23	0.36	<0.0001	Reference
300–500	14.5 ± 9.1	0.37	0.32	0.43	<0.0001	0.0282
500–700	15.5 ± 10.9	0.53	0.47	0.59	0.3829	<0.0001
700+	18.7 ± 13.4	0.58	0.53	0.64	0.0041	<0.0001
Interaction between time and IGF-1 value at baseline		–	–	–	0.0551

^aEffect size <0.50 indicates a favorable effect on acromegaly control.